Pelthos Therapeutics Inc. (PTHS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pelthos Therapeutics Inc. (PTHS) has a cash flow conversion efficiency ratio of -0.161x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.25 Million) by net assets ($38.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PTHS net asset quality index to measure how much of total assets are equity-financed.
Pelthos Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Pelthos Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore PTHS debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Pelthos Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pelthos Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Adocia
PA:ADOC
|
1.826x |
|
IDIS Holdings Co. Ltd
KQ:054800
|
0.019x |
|
Global Lithium Resources Ltd
AU:GL1
|
-0.020x |
|
Park Dental Partners, Inc. Common Stock
NASDAQ:PARK
|
0.039x |
|
Manas Enerji Yonetimi Sanayi & Ticaret AS
IS:MANAS
|
-0.018x |
|
Bak Ambalaj Sanayi ve Ticaret AS
IS:BAKAB
|
0.055x |
|
Three A Resources Bhd
KLSE:0012
|
0.049x |
|
Dwarikesh Sugar Industries Limited
NSE:DWARKESH
|
0.674x |
Annual Cash Flow Conversion Efficiency for Pelthos Therapeutics Inc. (2021–2025)
The table below shows the annual cash flow conversion efficiency of Pelthos Therapeutics Inc. from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see PTHS stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $38.88 Million | $-22.59 Million | -0.581x | -127.22% |
| 2024-12-31 | $-2.71 Million | $-5.79 Million | 2.134x | +1302.03% |
| 2023-12-31 | $-6.44 Million | $-981.03K | 0.152x | -64.00% |
| 2022-12-31 | $-3.71 Million | $-1.57 Million | 0.423x | -2.32% |
| 2021-12-31 | $-3.68 Million | $-1.59 Million | 0.433x | -- |
About Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus… Read more